Allied Corp. Begins Human Clinical PHASE I Research Trial for PTSD Pharmaceutical Product
ALID10 - Seite 2
For more information on Allied Corp., visit www.allied.health
About Allied Corp.
Allied
Corp. is an international medical cannabis production company with a mission to address today’s medical issues by researching, creating and producing targeted cannabinoid health solutions.
Allied Corp. uses an evidence-informed scientific approach to make this mission possible, through cutting-edge pharmaceutical research and development, innovative plant-based production and unique
development of therapeutic products.
About MGC Pharma:
MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable, standardised, high quality phytocannabinoid derived medicines for the growing demand
in the medical markets in Europe, North America and Australasia. The Company is initially targeting two widespread medical conditions – epilepsy and dementia – and has a number of products in the
development pipeline.
Employing its ‘Nature to Medicine’ strategy, MGC Pharma has a number of research collaborations with world renowned institutions and academia to optimise the development of targeted
phytocannabinoid derived medicine products prior to production in the Company’s EU-GMP Certified manufacturing facility. The Company has a growing patient base and through its global distribution
footprint via an extensive network of commercial partners, has the ability to supply the global market.
Investor Relations:
ir@allied.health
1-877-255-4337
Forward-Looking Statements:
This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or “forward-looking statements” made pursuant to the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and introduction of TACTICAL RELIEF branded products, and the use of proceeds from the offering of convertible notes.